IP Library Granted Patent US 9,376,437
Granted Patent B2
US 9,376,437 · App. 14/341,392 · Granted Jun 28, 2016

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,376,437
App. No.
14/341,392
Granted
Jun 28, 2016
Kind
B2
Abstract

This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.

Claims (10)

1. A compound having a formula (10)

or a salt thereof; wherein, R 1 and R 2 independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, carboxyl, haloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, aralkyl, hydroxyalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, aralkoxy, aralkylthio, alkanoyl, mercapto, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, heteroaryl, acyl, and heterocycle radicals, and wherein when R 1 represents CH 2 Ph, R 2 does not represent CH 2 -((2-CH 3 )-Ph.

2. The compound according to claim 1 , wherein R 1 is CH 2 Ph and R 2 is CH 2 -((2-Cl)-Ph).

3. The compound according to claim 1 , wherein R 1 is CH 2 Ph and R 2 is CH 2 -(2-thienyl).

4. The compound according to claim 1 , wherein R 1 is CH 2 Ph and R 2 is CH 2 CH 2 Ph.

5. The compound according to claim 1 , wherein R 1 is CH 2 Ph and R 2 is CH 2 CH 2 (4-N-benzyl-piperazine).

6. The compound according to claim 1 , wherein R 1 is CH 2 Ph and R 2 is CH 2 -(2,4-di F-Ph).

7. The compound according to claim 1 , wherein R 1 is H and R 2 is CH 2 -((2-CH 3 )-Ph.

8. The compound according to claim 1 , wherein R 1 is CH 3 and R 2 is CH 2 -((2-CH 3 )-Ph.

9. The compound according to claim 1 , wherein R 1 is CH 2 CH 2 Ph and R 2 is CH 2 -((2-CH 3 )-Ph.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2016
From: PROVID PHARMACEUTICALS INC.
To: ONCOCEUTICS, INC
Reel/Frame 037636/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2016
From: POTTORF, RICHARD S.; NALLAGANCHU, BHASKARA RAO; OLSON, GARY L.
To: PROVID PHARMACEUTICALS INC.
Reel/Frame 037636/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2015
From: STOGNIEW, MARTIN; ALLEN, JOSHUA E.
To: ONCOCEUTICS, INC.
Reel/Frame 035883/0482 →